Related
New BioMarin CEO Prioritizes Three Programs, Axes Four Others
Rare Daily Staff BioMarin Pharmaceutical said that after a strategic R&D asset review to maximize profitability, it […]
Read moreFDA Approves Pfizer’s Hemophilia B Gene Therapy
Rare Daily Staff The U.S. Food and Drug Administration approved Pfizer’s Beqvez, a gene therapy for the […]
Read moreModerna and OpenAI Collaborate to Advance mRNA Medicine
Rare Daily Staff Moderna and OpenAI announced an ongoing collaboration, which will integrate generative AI throughout the […]
Read moreRegeneron and Mammoth Collaborate on Next-Gen CRISPR Gene Editing for Multiple Diseases
Rare Daily Staff Regeneron Pharmaceuticals and Mammoth Biosciences entered a collaboration to research, develop and commercialize in […]
Read moreRett Syndrome Research Trust Partners with Vivalink to Accelerate Research
Rare Daily Staff Digital health technology provider Vivalink entered into a collaboration with the Rett Syndrome Research […]
Read moreLabcorp to Acquire Invitae Assets
Rare Daily Staff Laboratory services company Labcorp said it’s $239 million bid for assets of the medical […]
Read morePerrigo Receives Offer to Divest its Rare Diseases Business for up to $295 Million
Rare Daily Staff Perrigo Company, a provider of consumer self-care products, said that Spanish pharmaceutical company Esteve […]
Read moreAddressing a Shortage of Genetic Counselors with AI
As genetic testing continues to expand, it is bringing into focus a shortage of genetic counselors who […]
Read moreEndeavor Bio Raises $132.5 Million to Advance Pipeline
Rare Daily Staff Endeavor BioMedicines raised $132.5 million in a series C financing, including the conversion of […]
Read more